Epistem Hldgs Plc (LON:EHP) , the Manchester based biotech company focused on commercialising epithelial stem cell technology, announced that it signed a distribution deal with Veritas Corporation to distribute Epistem's contract research services in the Japanese market. This agreement will extend Epistem's reach into the Japanese pharmaceutical market for its preclinical efficacy testing using its extensive epithelial stem cell expertise in oncology, inflammatory bowel disease (IBD) and dermatology applications.
EHP shares have appreciated by 5% over the last year. Epistem Holdings Plc is currently graded C by LCF Research.
